There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

Background Intravenous (IV), intramuscular (IM), and subcutaneous (SC) are the three most
frequently used injection routes in medication administration. Comparative studies of SC …

ENHANZE® drug delivery technology is based on the proprietary recombinant human
hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the …

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …

Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable
responses to many patients with solid and haematological cancers. The high prices and …

Biotherapeutics is a rapidly growing drug class, and over 200 biotherapeutics have already
obtained approval, with about 50 of these being approved in 2015 and 2016 alone. Several …

Background The aim of this study was to evaluate patient preference and satisfaction for the
subcutaneous (sc) versus intravenous (iv) formulation of rituximab given with chemotherapy …

Background Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma,
and is administered over 1· 5–6 h. A subcutaneous formulation could reduce patients' …

Background Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA
trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not …

CD20 monoclonal antibodies (CD20 mAb) induce cellular cytotoxicity, which is traditionally
measured by antibody-dependent cellular cytotoxicity (ADCC) assays. However, data …